Pharmacogenetic Testing in Primary Care and Prevention

Dear Colleagues,

The increasing implementation of pharmacogenetic (PGx) testing brings challenges and excitement. Like other testing applications in personalized and precision medicine, PGx testing is increasingly being used in healthy individuals and in patients with common, chronic diseases and to affect risk factors for cardiovascular disease and cancer. Can PGx testing be used for precision prescribing, and ultimately improve clinical outcomes in healthy populations and for primary and for secondary prevention in patients with conditions commonly managed in primary care -- like hypertension, hyperlipidemia, type 2 diabetes, and depression. Although feasible guidelines have been developed to promote the clinical practice of these tests, performing meaningful PGx tests requires the correlation of pharmacogenetic variation with clinical effectiveness data, including measurement of outcomes and costs at the patient, provider, system, or economic levels. This Special Issue focuses on the clinical application of pharmacogenetic testing in primary care and prevention contexts. It includes, but is not limited to, population-based studies on genetic variation in the toxicity and efficacy of commonly used drugs, multi-omics studies for determining therapeutic and toxicity response, determination of epigenetic changes in drug response/resistance, and the implementation of pharmacogenetic testing results into routine clinical interactions.

Dr. Latha Palaniappan
Guest Editor

Dr. Sean P. David
Dr. Deepak Voora
Co-Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.